Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chalk, C. H.
Right arrow Articles by Windebank, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chalk, C. H.
Right arrow Articles by Windebank, A. J.
NEUROLOGY 1993;43:2209
© 1993 American Academy of Neurology

Seronegativity for type 1 antineuronal nuclear antibodies ('anti-Hu') in subacute sensory neuronopathy patients without cancer

Colin H. Chalk, MD, CM, FRCP(C), Vanda A. Lennon, MD, PhD, J. Clarke Stevens, MD and Anthony J. Windebank, MD

Department of Neurology, Mayo Clinic, Rochester, MN (Drs. Chalk, Lennon, and Windebank), and the Mayo Clinic, Scothdale, AZ (Dr. Stevens).

We followed 21 patients with sensory neuronopathy without evidence of cancer for up to 23 years. All were seronegative for type 1 antineuronal nuclear antibodies (ANNA-1, also called "anti-Hu"). We additionally studied 67 seropositive patients with sensory neuronopathy or a related neurologic syndrome. Ninety-one percent of the seropositive patients had a small-cell lung carcinoma. One, with a normal chest x-ray, had been followed for 7 years for sensory neuronopathy of indeterminate cause before serologic testing for ANNA-1 led to the discovery of the tumor by CT. We conclude that ANNA-1 seropositivity in a patient with sensory neuronopathy is strong evidence for an underlying small-cell lung cancer.

Address correspondence and reprint requests to Dr. Anthony J. Windebank, Mayo Clinic and Mayo Foundation, Department of Seurology, 1501 Guggenheim Building, 200 First Street, SW, Rochester, MN 55905.

Supported in part by a grant from the National Cancer Institute (CA 37343).

Received January 26, 1993. Accepted for publication in final form April 14, 1993.




This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
T. Shimoda, W. Koizumi, S. Tanabe, K. Higuchi, T. Sasaki, N. Nakayama, M. Azuma, K. Saigenji, T. Katou, and M. Ogino
Small-Cell Carcinoma of the Esophagus Associated with a Paraneoplastic Neurological Syndrome: A Case Report Documenting a Complete Response
Jpn. J. Clin. Oncol., February 1, 2006; 36(2): 109 - 112.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by AAN Enterprises, Inc.